

# Managing Medical Abortions

---

DR. LAURA KROEKER, CCFP



# Disclosures

---

## Affiliations:

- I have no relationships with for-profit or not-for-profit organizations.

## Financial Support:

- This session/program has not received financial or in-kind support.



# Objectives

---

1. Outline the indications, contraindications, and work up for medical abortion
2. Explain the medical abortion procedure
3. Review the after care and complications for a patient who has had a medical abortion
4. Identify providers of medical abortion across Northern Ontario to establish a contact list for referring physicians

# Medical abortion vs Surgical abortion

---

Medical abortion	Surgical abortion
Highly effective (97-99%)	Highly effective (99%)
(Usually) <b>avoids surgery</b> , although usually <b>more pain and bleeding</b> than with surgery	May be done with sedation/anesthesia
Can take <b>days to complete</b>	Completed rapidly
<b>Heavy bleeding</b> , more than a period	Light bleeding
Usually <b>2-3 visits</b>	Usually 1-2 visits
<b>Can be done at home</b>	Cannot be done at home

Types of surgical abortion:

Up to 10 weeks GA: Manual vacuum aspiration

Up to 13 weeks GA: Suction and curettage

Up to 24 weeks (location dependent): Dilation and evacuation

# Medical abortion regimens

---

Misoprostol alone (uncommon)

Methotrexate and misoprostol (not approved by Health Canada)

- Up to 7-8 weeks GA

Mifepristone and misoprostol

- Up to 9-10 weeks GA



# Mifepristone and misoprostol

---

## **November 2017:**

- approved for up to 63 days gestation (9 weeks)
- can be dispensed like any other drug
- prescribers no longer have to do the mandatory education modules

# Training?

---

**CPSO: It is the professional responsibility of a physician to ensure that they have sufficient knowledge, skills and judgement to competently prescribe any medication and supervise patient care**


Module through SOGC eLearning portal – developed by the SOGC, the CFPC, and the Canadian Pharmacists Association (\$\$)

Also an educational program online from celopharma - <http://celopharma.com/en/health-professionals/> (free)

# Mifepristone

---

- Works at the decidua (endometrium) by blocking progesterone receptors (endometrial degeneration) and releasing endogenous prostaglandins (uterine contractility)
- Also strongly blocks glucocorticoids and weakly blocks androgens





# Whitefriestone

**Interactions and effectiveness decreased by**

- Mifepristone may increase or alter CYP3A effects, including those
- Mifepristone irreversibly inhibits CYP3A4 enzymes (may be an
- CYP3A4 inducer, severe T/HG), meprobolam, and
- issue if patient has a history of dependence on mifepristone drug levels increased by
- triptans
- carbamazepine, diazepam, St
- acetaminophen, NSAIDs, aspirin and antiplatelets
- inhibitors (e.g./ ketoconazole,
- (ondansetron, metoprolol, diltiazem, spiroprone, grapefruit juice)
- John's Wort, barbiturates, doxylamine+pyridoxine) are **NOT** contraindicated

# Misoprostol

---

Synthetic prostaglandin E1 – causes cervical softening and uterine contractions

Also acts on GI tract smooth muscle – nausea, vomiting, diarrhea

Side effects: can make people feel like they have a 24hr 'flu' – headache, fever, fatigue, nausea, vomiting, diarrhea

**No known drug interactions**

# Absolute contraindications to MA

---

- Known ectopic pregnancy
- Chronic adrenal failure
- Inherited porphyria
- **Uncontrolled asthma**
- Known hypersensitivity to mifepristone or misoprostol
- **Ambivalence in the abortion decision**

# Relative contraindications to MA

---

- Unconfirmed gestational age
  - resolve by ordering an U/S
- Intrauterine device (IUD) in place
  - resolve by removing the IUD and ordering an U/S to rule out ectopic
- Concurrent long term corticosteroid therapy
  - if not life-threatening to have a small period of reduced efficacy, may be able to just increase steroid dose for 3-4 days after mifepristone administration
- Bleeding disorder or anticoagulation
  - women with severe anemia (Hb < 95g/L) and bleeding disorders should not undergo MA

# First visit:



1. Ensure certainty of decision, adequate social support, access to a phone, & ability to follow up
  - Offer SW referral (not required)
2. Counsel re: risks, benefits, complications, need for follow up, need for access to emergency care x 14 days
3. Ensure no contraindications
4. Screen for/treat STIs
  - routine urine screening for chlamydia/gonorrhea is recommended by SOGC
5. Check vitals and consider doing a pelvic exam
6. Order serum bHCG and Rh factor (if unknown), Hb if concerned re: anemia
7. Arrange an ultrasound for dating/location if uncertain of dates/risk factors for ectopic

# Is an U/S always needed?

---

**No**

U/S is needed when there are risk factors for ectopic pregnancy or when dating cannot be reliably determined

# Interpreting early dating U/S with bHCG

---

<7wks gestation may not be able to find intrauterine pregnancy on U/S

If low risk for ectopic, can proceed if:

- bHCG  $\leq 2000$  IU/L and no gestational sac
- or
- a likely gestational sac with no yolk sac or fetal pole

**32-33 days post LMP: bHCG >1500 IU/L, gestational sac visible in uterus (measuring 2-3mm and growing about 1mm/day)**

**35-42 days post LMP: bHCG 7200-10800 IU/L, yolk sac apparent in gestational sac (confirms IUP)**

**40-49 days post LMP: fetal pole apparent adjacent to yolk sac (3.4mm at 42 days and grows about 1mm/day – when reaches 10mm interpreted as 7w+0 to 7w+2)**

**<8 weeks (56 days): CRL <17mm**

**<9 weeks (63 days): CRL <23mm**

**<10 weeks (70 days): CRL <30mm**

# Second visit:

---

1. Review again expected side effects/when to seek reassessment
2. Review contraception plan
3. Instruct how to take
  - 200mg mifepristone swallowed with water
  - If Rh-, also give 120-300mcg RhIG on the day of mifepristone or within 72hrs of bleeding
  - 24-48hrs later 800mcg misoprostol buccally or vaginally
  - 24hrs later OCP/depo or 7 days later IUD
4. May want to prescribe an analgesic (e.g./ NSAID) or antiemetic
5. Give req for serum bHCG to be done in 7-14 days
6. Book f/u and ensure pt has clinic number, telehealth/ER number
7. Offer SW referral if not done previously



# Signed co

Not required, however

## Mifegymiso Patient Consent Form

Mifegymiso (mifepristone and misoprostol) for termination of first trimester pregnancy

1. I have been given the Mifegymiso (mifepristone and misoprostol) to end my pregnancy.
2. I discussed the information with my Health Care Professional.
3. My Health Care Professional has explained to me the risks and benefits of taking Mifegymiso (mifepristone and misoprostol) to end my pregnancy.
4. I understand that I will take the tablets within 7-14 days (1-2 weeks) of my last menstrual period.
5. I understand that I will take the tablets within 7-14 days (1-2 weeks) of my last menstrual period.
6. My Health Care Professional has explained to me the risks and benefits of taking Mifegymiso (mifepristone and misoprostol) to end my pregnancy.
7. Bleeding and cramping will occur within 7-14 days (1-2 weeks) of my last menstrual period.
8. I know that in some cases, the pregnancy may continue after treatment with Mifegymiso (mifepristone and misoprostol).
9. I understand that if my pregnancy continues after treatment with Mifegymiso (mifepristone and misoprostol), I may have choices, which may include continuing the pregnancy or having a surgical procedure.
10. I understand that if the pregnancy continues after treatment with Mifegymiso (mifepristone and misoprostol), I may need a surgical procedure or if I need a surgical procedure, I will need a surgical procedure.
11. I have my Health Care Professional's advice about when to take the tablets.
12. I have decided to take Mifegymiso (mifepristone and misoprostol) to end my pregnancy.
13. I must ensure that I have someone with me when I take the tablets.
14. I will do the following:
  - Contact my Health Care Professional, that lasts for 24 hours.
  - Contact my Health Care Professional, pads per hour for 24 hours.
  - Contact my Health Care Professional, including weakness, dizziness, or fainting.
  - Take the Patient Information Leaflet that they understand.
  - Have a follow-up 7-14 days after taking the tablets.

☐ I have made the decision to end my pregnancy without coercion and without pressure.

Patient name (print): \_\_\_\_\_

Patient signature: \_\_\_\_\_

The patient has signed the Patient Consent Form for the Mifegymiso Medication.

Health Care Professional name: \_\_\_\_\_

Health Care Professional signature: \_\_\_\_\_

After the patient and the Health Care Professional have signed the Patient Consent Form, the Health Care Professional will provide a copy to the patient before she leaves the clinic.

\*Health Care Professional must keep white top copy for files and provide pink copy to patient.

**Mifegymiso**  
**Mifepristone and Misoprostol**  
for termination of first  
trimester pregnancy

Mifegymiso

da

<https://www.shorecentre.ca/wp-content/uploads/NBW-Mifegymiso-Information-Brochure-min.pdf>

# Writing the prescription

---

- Call the pharmacy re: timeline
- Make sure the pharmacist knows how to get the cost covered



# Troubleshooting

---

- Pain
  - Heat, cold
  - NSAIDs have more evidence than acetaminophen
  - Safe to use NSAIDs, acetaminophen, weak opioids (unless otherwise contraindicated)
  - If severe, send to ER
- Nausea
  - Dimenhydrinate, ondansetron, doxylamine+pyridoxine
  - If vomit >1hr after dose of misoprostol or mifepristone, no new prescription needed
- Prolonged but not severe bleeding, or bleeding re-starts
  - Average length of bleeding about 2 weeks (up to 4 weeks)
  - Repeat dose of misoprostol 400-800mcg – consider vaginal administration
- Well, but retained products on U/S
  - Normal
  - Consider U/S again after next normal period

# Third visit (follow-up)

---

1. Confirm completion
  - Serum bHCG should drop >50% 24-48hrs after misoprostol and drop >80% by follow up at 7-14 days
  - Can also assess with U/S
2. Assess for complications
  - 'retained products' on U/S in an otherwise well patient is not a complication
3. Reinforce contraceptive plans/provide contraception
  - Urine bHCG may remain positive for a month or longer post-medical abortion

# Billing

---

## **A920** – initiation of medical abortion (second visit)

- Counselling/consult fee absorbed into this code
- \$161.15

## **A921** – follow-up visit

- Confirm that abortion is complete, review contraception
- \$33.70



# Support

---



## CAPS CPCA

Canadian Abortion Providers Support  
Communauté de pratique canadienne sur l'avortement



THE COLLEGE OF  
FAMILY PHYSICIANS  
OF CANADA



LE COLLÈGE DES  
MÉDECINS DE FAMILLE  
DU CANADA



CANADIAN  
PHARMACISTS  
ASSOCIATION

ASSOCIATION DES  
PHARMACIENS  
DU CANADA

**CART-GRAC**

Contraception  
Access  
Research  
Team



Groupe de  
recherche sur  
l'accessibilité à  
la contraception

**INSPQ**

INSTITUT NATIONAL  
DE SANTÉ PUBLIQUE  
DU QUÉBEC

# Where else to direct patients?

---



**Action Canada**  
**for Sexual Health & Rights**

Action Canada for Sexual Health & Rights  
– 1-888-642-2725



[Choiceconnect.ca](http://Choiceconnect.ca)

# Questions?

---



# References

---

Accredited Medical Abortion Training Program, Society of Obstetricians and Gynecologists of Canada (currently unavailable due to recent website redesign, original eLearning platform used is inactive)

Health Canada, Government of Canada, <http://healthycanadians.gc.ca/>

Medical Abortion. Costescu, DustinGuilbert, EdithBernardin, JeanneBlack, AmandaDunn, SheilaFitzsimmons, BrianNorman, Wendy V.Pymar, HelenSoon, JudithTrouton, KoniahWagner, Marie-SoleilWiebe, Ellen et al. Journal of Obstetrics and Gynaecology Canada , Volume 38, Issue 4, 366 - 389

Mifegymiso (mifepristone, misoprostol) Educational program for health care professionals. Celopharma Inc. November 2017. [http://celopharma.com/wp-content/files\\_mf/training-program-EN.pdf](http://celopharma.com/wp-content/files_mf/training-program-EN.pdf)

Mifegymiso Mifepristone and Misoprostol for termination of first trimester pregnancy. Celopharma Inc.

Canadian Abortion Providers Support (CAPS-CPCA), [www.caps-cpca.ubc.ca](http://www.caps-cpca.ubc.ca)

# References

---

Canadian Institute for Health Information, Induced Abortions Reported in Canada in 2017, <https://www.cihi.ca/sites/default/files/document/induced-abortion-2017-en-web.xlsx>

Bernard N, Elefant E, Carlier P, Tebacher M, Barjhoux C, Bos-Thompson M, Amar E, Descotes J, Vial T. Continuation of pregnancy after first-trimester exposure to mifepristone: an observational prospective study. *BJOG* 2013;120:568–575.

The Additive Value of Pelvic Examinations to History in Predicting Sexually Transmitted Infections for Young Female Patients With Suspected Cervicitis or Pelvic Inflammatory Disease. *Ann Emerg Med*. 2018 Dec;72(6):703-712.e1. doi: 10.1016/j.annemergmed.2018.05.004. Epub 2018 Jul 2

Vauzelle C1, Beghin D, Cournot MP, Elefant E. Birth defects after exposure to misoprostol in the first trimester of pregnancy: prospective follow-up study. *Reprod Toxicol*. 2013 Apr;36:98-103. doi: 10.1016/j.reprotox.2012.11.009. Epub 2012 Dec 1.

Murray et al, Patients' Motivation for Surgical Versus Medical Abortion, *JOGC* Sept 2019, volume 41, issue 9, 1325-1329.

Soon, Judith and N. Rebic, Guide for Dispensing Mifegymiso for Medical Abortion, available at: [https://www.caps-cpca.ubc.ca/AnnokiUploadAuth.php/8/80/Canadian\\_Medical\\_Abortion\\_Dispensing\\_Guide\\_V8\\_2018-10-18.pdf](https://www.caps-cpca.ubc.ca/AnnokiUploadAuth.php/8/80/Canadian_Medical_Abortion_Dispensing_Guide_V8_2018-10-18.pdf)

# References

---

Ireland LD, Gatter M, Chen AY. Medical Compared With Surgical Abortion for Effective Pregnancy Termination in the First Trimester. *Obstet Gynecol*. 2015 Jul;126(1):22-8. doi: 10.1097/AOG.0000000000000910. PMID: 26241252.